18th Feb 2021 14:31
Avacta Group PLC - AIM-listed developer of Affimer biotherapeutics and reagents - Receives approval from the Medicines & Healthcare Products Regulatory Agency for its Clinical Trial Authorisation in the UK for a phase I study of its lead pre|Cision pro-drug, AVA6000 pro-doxorubicin. If the AVA6000 study shows that the pre|CISION chemistry is effective in reducing systemic toxicity of doxorubicin in humans, then it can be applied to a range of other established chemotherapies to improve their safety and efficacy, Avacta notes.
Current stock price: 188.02 pence
Year-to-date change: up 65%
By Evelina Grecenko; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Avacta Group